HRP20201848T1 - Bispecifična egfr/c-met antitijela - Google Patents

Bispecifična egfr/c-met antitijela Download PDF

Info

Publication number
HRP20201848T1
HRP20201848T1 HRP20201848TT HRP20201848T HRP20201848T1 HR P20201848 T1 HRP20201848 T1 HR P20201848T1 HR P20201848T T HRP20201848T T HR P20201848TT HR P20201848 T HRP20201848 T HR P20201848T HR P20201848 T1 HRP20201848 T1 HR P20201848T1
Authority
HR
Croatia
Prior art keywords
cancer
antibody
egfr
met
amino acid
Prior art date
Application number
HRP20201848TT
Other languages
English (en)
Inventor
Mark Chiu
Sheri MOORES
Joost Neijssen
Paul Parren
Janine Schuurman
Original Assignee
Janssen Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50728148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20201848(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Biotech, Inc. filed Critical Janssen Biotech, Inc.
Publication of HRP20201848T1 publication Critical patent/HRP20201848T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (11)

1. Izolirano bispecifično (c-Met) antitijelo specifično za receptor epidermalnog faktora rasta (EGFR)/receptor faktora rasta hepatocita, koje sadrži: a) prvi teški lanac (HC1) koji sadrži HC1 konstantnu domenu 3 (HC1 CH3) i HC1 varijabilnu regiju 1 (VH1); b) drugi teški lanac (HC2) koji sadrži HC2 konstantnu domenu 3 (HC2 CH3) i HC2 varijabilnu regiju 2 (VH2); c) prvi laki lanac (LC1) koji sadrži varijabilnu regiju 1 lakog lanca (VL1); i d) drugi laki lanac (LC2) koji sadrži varijabilnu regiju 2 lakog lanca (VL2), pri čemu se VH1 i VL1 spajaju radi stvaranja prvog mjesta za vezivanje antigena koji specifično veže EGFR, VH2 i VL2 se spajaju radi stvaranja drugog mjesta za vezivanje antigena koji specifično veže c-Met, HC1 sadrži najmanje jednu zamjenu u HC1 CH3 i HC2 sadrži najmanje jednu zamjenu u HC2 CH3, i zamjenu u HC1 CH3 i zamjenu u HC2 CH3 koja se pojavljuje na različitim položajima ostatka aminokiselina, kada je numeriranje ostataka u skladu sa EU indeksom, gdje i) VH1 sadrži regiju određivanja komplementarnosti teškog lanca (HCDR) 1 (HCDR1), HCDR2 i HCDR3 aminokiselinskih sekvenci SEQ ID NOs: 210, 211 i 212, tim redom; i ii) VL1 sadrži regiju određivanja komplementarnosti lakog lanca (LCDR) 1 (LCDR1), LCDR2 i LCDR3 aminokiselinskih sekvenci SEQ ID NOs: 213, 214 i 215, tim redom; i iii) VH2 sadrži HCDR1, HCDR2, i HCDR3 aminokiselinskih sekvenci SEQ ID NOs: 216, 217 i 218, tim redom; i iv) VL2 sadrži LCDR1, LCDR2 i LCDR3 aminokiselinskih sekvenci SEQ ID NOs: 219, 220 i 221, tim redom.
2. Bispecifično antitijelo prema zahtjevu 1, gdje: a) antitijelo je ljudsko antitijelo u kome VH1, VL1, VH2 i VH2 sadrže sekvencu aminokiselina SEQ ID NOs: 189, 190, 193 i 194, tim redom; i/ili b) antitijelo inhibira fosforilaciju kinaza 1 i 2 koje su povezane sa izvanstaničnim signalom (ERK1/2) u NCI-H292, NCI-H1975 ili SKMES-1 staničnoj liniji sa IC50 vrijednosti koja je najmanje 10-puta manja, najmanje 20-puta manja, najmanje 30-puta manja, najmanje 40-puta manja, najmanje 50-puta manja ili najmanje 60-puta manja u usporedbi sa IC50 vrijednosti inhibiranja fosforilacije ERK1/2 u NCI-H292, NCI-H1975 ili SKMES-1 staničnim linijama sa smjesom kontrolnog monovalentnog EGFR antitijela koji sadrži teški lanac 3 (HC3) i laki lanac 3 (LC3) i kontrolno monovalentno c-Met antitijelo koje sadrži teški lanac 4 (HC4) i laki lanac 4 (LC4), pri čemu HC3 i HC1, LC3 i LC1, HC4 i HC2, i LC4 i LC2 imaju redom identične sekvence aminokiselina, i fosforilacija ERK1/2 se mjeri u cijelim staničnim lizatima pomoću sendvič imunotesta upotrebom antifosfo ERK1/2 antitijela kao antitijela za hvatanje i antitijela koja se vežu za nefosforilni i fosforilni ERK1/2 koji je konjugiran sa elektrohemiluminscentnim spojem kao antitijelom za detekciju, opcionalno gdje: i) antitijelo inhibira fosforilaciju ERK1/2 sa IC50 vrijednosti 2x10-9 M ili manje, 1x10-9 M ili manje, ili 1x10-10 M ili manje; i/ili ii) ERK1 je fosforilan na položajima Thr202 i Tyr204, i ERK2 je fosforilan na ostacima Thr185 i Tyr197; i/ili i/ili; c) antitijelo koje inhibira fosforilaciju proteina kinaze B (AKT) na Ser473 u NCI-H1975 staničnoj liniji sa IC50 vrijednosti koja je najmanje 70-puta manja kada se usporedi sa IC50 vrijednosti inhibiranja fosforilacije AKT na Ser473 u NCI-H1975 staničnoj liniji s smjesom kontrolnog monovalentnog EGFR antitijela koje sadrži HC3 i LC3 i kontrolnog monovalentnog c-Met antitijela koje sadrži HC4 i LC4, gdje HC3 i HC1, LC3 i LC1, HC4 i HC2, i LC4 i LC2 imaju redom identične sekvence aminokiselina, i fosforilacija AKT na Ser473 se mjeri u cijelim staničnim lizatima sendvič imunotestom upotrebom antitijela koje se veže za nefosforilni i fosforilni AKT kao antitijelo za hvatanje i anti-fosfoAKT Ser473 antitijelom konjugiranim s elektrohemiluminiscentnim spojem kao antitijelo za detekciju, opcionalno gdje antitijelo inhibira fosforilaciju AKT na Ser473 s IC50 vrijednosti 1x10-9 M ili manje; i/ili d) antitijelo koje inhibira fosforilaciju AKT na Thr308 u NCI-H1975 staničnoj liniji s IC50 vrijednosti koja je najmanje 100-puta manja u usporedbi s IC50 vrijednosti inhibiranja fosforilacije AKT na Thr308 u NCIH1975 staničnoj liniji s smjesnom kontrolnog monovalentnog EGFR antitijela koje sadrži HC3 i LC3 kontrolno monovalentno c-Met antitijelo koje sadrži HC4 i LC4, gdje HC3 i HC1, LC3 i LC1, HC4 i HC2, i LC4 i LC2 imaju redom identične sekvence aminokiselina, i fosforilacija AKT na Thr308 se mjeri u cijelim staničnim lizatima sendvič imunotestom upotrebom antitijela koje se vezuje za nefosforilni i fosforilni AKT kao antitijelo za hvatanje i antifosfo AKT Thr308 antitijelom konjugiranim s elektrohemiluminiscentnim spojem kao antitijelo za detekciju, opcionalno gdje antitijelo inhibira fosforilaciju AKT na Thr308 s IC50 vrijednosti od 1x10-9 M ili manje; i/ili; e) bispecifično antitijelo veže EGFR koje ima sekvencu aminokiselina prikazanu u SEQ ID NO: 73 na EGFR ostacima K489, 1491, K467 i S492 i c-Met na ostacima PEFRDSYPIKYVHAF (SEQ ID NO: 238) i FAQSKPDSAEPMDRSA (SEQ ID NO: 239); i/ili f) antitijelo inhibira rast NCI-H292 ili NCI-H1975 stanica s IC50 vrijednosti koja je najmanje 300-puta manja, najmanje 400-puta manja, najmanje 500-puta manja, najmanje 600-puta manja, najmanje 700-puta manja ili najmanje 800-puta manja u usporedbi s IC50 vrijednosti inhibiranja rasta NCI-H292 ili NCI-H1975 stanica sa cetuksimabom kada se NCI-H292 ili NCI-H1975 stanice uzgajaju u uvjetima koji osiguravaju nisko vezivanje; i/ili g) antitijelo inhibira rast SKMES-1 tumorskih stanica koje eksprimiraju HGF u SCID Beige miševima s postotkom (%) T/C vrijednosti od najmanje 500-puta manje u danu 36 u usporedbi scetuksimabom, kada se bispecifično antitijelo i cetuksimab daju u dozi od 20 mg/kg ; i/ili; h) antitijelo neutralizira EGFR i c-Met signalne puteve.
3. Bispecifično antitijelo prema zahtjevu 1 ili zahtjevu 2, pri čemu HC1 i HC2 su od IgG1, IgG2, IgG3 ili IgG4 izotipa, na primjer gdje HC1 i HC2 su od IgG1 izotipa; opcionalno gdje HC1 CH3 sadrži najmanje jedan, dva, tri, četiri, pet, šest, sedam ili osam zamjena i HC2 CH3 sadrži najmanje jednu, dvije, tri, četiri, pet, šest, sedam ili osam zamjena na položajima ostatka 350, 366, 368, 370, 399, 405, 407 ili 409, pri čemu je numeriranje ostataka u skladu sa EU indeksom, što je a) gdje HC1 CH3 sadrži najmanje jednu, dvije, tri ili četiri zamjene i HC2 CH3 sadrži najmanje jednu, dvije, tri ili četiri zamjene na položajima ostataka 350, 370, 405 ili 409; b) gdje HC1 CH3 sadrži najmanje jednu zamjenu i HC2 CH3 sadrži najmanje jednu zamjenu na položajima ostataka 405 ili 409; c) gdje HC1 CH3 sadrži K409R ili F405L zamjenu i HC2 CH3 sadrži K409R ili F405L zamjenu; ili d) gdje HC1 CH3 sadrži F405L zamjenu i HC2 CH3 sadrži K409R zamjenu.
4. Bispecifično antitijelo prema bilo kojem od zahtjeva 1 do 3, (a) koje dalje sadrži 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 ili 15 konzervativnih zamjena aminokiselina u HC1, LC1, HC2 ili LC2, koji opcionalno sadrži zamjenu M252Y/S254T/T256E u HC1 i/ili HC2, pri čemu je numeriranje ostataka u skladu sa EU indeksom; i/ili (b) gdje antitijelo ima biantenarnu strukturu glikana sa sadržajem fukoze između 1 do 15%.
5. Farmaceutski sastav koji sadrži bispecifično antitijelo prema bilo kojem od zahtjeva 1 do 4 i farmaceutsko prihvatljivi nosač.
6. Bispecifično antitijelo prema bilo kojem od zahtjeva 1 do 4 za upotrebu u postupku liječenja raka, koji obuhvaća davanje terapeutski efikasne količine bispecifičnog EGFR/c-Met antitijela pacijentu kojem je potrebno u vremenskom periodu koji je dovoljan za liječenje raka, opciono gdje: a) rak je povezan sa mutacijom koja aktivira EGFR, umnožavanjem gena za EGFR, povećanim nivoima kruženja HGF, mutacijom koja aktivira c-Met, umnožavanjem gena za c-Met ili mutiranim KRAS, kao što je: (i) mutacija koja aktivira EGFR je G719A, G719X (pri čemu je X bilo koja aminokiselina), L861X (pri čemu je X bilo koja aminokiselina), L858R, E746K, L747S, E749Q, A750P, A755V, V765M, L858P ili T790M zamjena, brisanje E746-A750, brisanje R748-P753, unos Ala (A) između M766 i A767, unos Ser, Val i Ala (SVA) između S768 i V769, i unos Asn i Ser (NS) između P772 i H773, opcionalno gdje mutacija koja aktivira EGFR je L858R, del(E476, A750) i/ili T790M zamjena; ili (ii) mutirani KRAS ima G12V ili G12C zamjenu; ili (iii) subjekt je otporan ili je stekao otpornost na liječenje s erlotinibom, gefitinibom, afatinibom, CO-1686, AZD9192 ili cetuksimabom; ili (iv) rak je rak epitelnih stanica, rak grudi, rak jajnika, rak pluća, ne-sitnostanični rak pluća (NSCLC), adenokarcinom pluća, rak malih stanica pluća, kolorektalni rak, analni rak, rak prostate, rak bubrega, rak mjehura, rak glave i vrata, rak ždrijela, rak nosa, rak gušterače, rak kože, oralni rak, rak jezika, rak jednjaka, vaginalni rak, i rak vrata maternice, rak slezena, rak testisa, rak želuca, rak prsne žlijezde, rak debelog crijeva, rak štitne žlijezde, rak jetre, hepatocelularni rak (HCC) ili sporedni ili sporadični rak papilarnih bubrežnih stanica(PRCC); ili b) subjekt je homozigot za fenilalanin na položaju 158 od CD16 ili heterozigot za valin i fenilalanin na položaju 158 od CD16.
7. Bispecifično antitijelo za upotrebu prema zahtjevu 6 (a)(iv), koja obuhvaća davanje drugog terapeutskog sredstva, opcionalno gdje: a) drugo terapeutsko sredstvo je hemoterapeutsko sredstvo ili ciljana protiv raka terapija, kao što je: i) hemioterapeutsko sredstvo je cisplatin ili vinblastin; ili ii) hemioterapeutsko sredstvo ili ciljana protiv raka terapija je tirozin kinazni inhibitor EGFR, c-Met, HER2, HER3, HER4 ili VEGFR, opcionalno gdje je tirozin kinazni inhibitor erlotinib, gefitinib ili afatinib; ili b) drugo terapeutsko sredstvo se daje istovremeno, stupnjevito ili odvojeno.
8. Postupak in vitro inhibiranja rasta ili proliferacije stanica koje eksprimiraju EGFR i/ili c-Met, koji obuhvaća kontakt stanica sa bispecifičnim antitijelom prema bilo kojem od zahtjeva 1-4.
9. Bispecifično antitijelo prema bilo kojem od zahtjeva 1 do 4 za upotrebu u postupku inhibiranja rasta ili metastaza tumora ili stanica raka koje eksprimiraju EGFR i/ili c-Met kod subjekta koji obuhvaća davanje subjektu efikasne količine bispecifičnog antitijela za inhibiranje rasta ili metastaza tumora ili raka stanica koje eksprimiraju EGFR i/ili c-Met, opcionalno gdje je tumor koji eksprimira EGFR i/ili c-Met rak epitelnih stanica, rak grudi, rak jajnika, rak pluća, ne-sitnostanični rak pluća (NSCLC), adenokarcinom pluća, rak malih stanica pluća, kolorektalni rak, analni rak, rak prostate, rak bubrega, rak mjehura, rak glave i vrata, rak ždrijela, rak nosa, rak gušterače, rak kože, oralni rak, rak jezika, rak jednjaka, vaginalni rak, rak vrata maternice, rak slezena, rak testisa, rak želuca, rak prsne žlijezde, rak debelog crijeva, rak štitne žlijezde, rak jetre, hepatocelularni karcinom (HCC) ili sporedni ili nasljedni rak papilarnih stanica (PRCC), kao što gdje je tumor koji eksprimira EGFR i/ili c-Met povezan sa mutacijom koja aktivira EGFR, umnožavanjem gena za EGFR, povećanim nivoima kruženja HGF, mutacijom koja aktivira c-Met, umnožavanjem gena za c-Met ili mutiranog KRAS, opcionalno gdje: a) mutacija koja aktivira EGFR je G719A, G719X (pri čemu je X bilo koja aminokiselina), L861X (pri čemu je X bilo koja aminokiselina), L858R, E746K, L747S, E749Q, A750P, A755V, V765M, L858P ili T790M zamjena, brisanje E746-A750, brisanje R748-P753, unos Ala (A) između M766 i A767, i unos Ser, Val i Ala (SVA) između S768 i V769, i unos Asn i Ser (NS) između P772 i H773; ili b) mutirani KRAS ima G12V ili G12C zamjenu.
10. Bispecifično antitijelo prema bilo kojem od zahtjeva 1 do 4 za upotrebu u terapiji, kao što je za upotrebu u liječenju raka, opcionalno kada je rak rak epitelnih stanica, rak grudi, rak jajnika, rak pluća, ne-sitnostanični rak pluća (NSCLC), adenokarcinom pluća, rak malih stanica pluća, kolorektalni rak, analni rak, rak prostate, rak bubrega, rak mjehura, rak glave i vrata, rak ždrijela, rak nosa, rak gušterače, rak kože, oralni rak, rak jezika, rak jednjaka, vaginalni rak, rak vrata maternice, rak slezena, rak testisa, rak želuca, rak prsne žlijezde, rak debelog crijeva, rak štitne žlijezde, rak jetre, hepatocelularni karcinom (HCC) ili sporedni ili nasljedni karcinom papilarnih stanica bubrega (PRCC).
11. Bispecifično antitijelo za upotrebu prema zahtjevu 10, gdje je bispecifično antitijelo davano u kombinaciji s drugim terapeutskim agensom, istovremeno, stupnjevito ili odvojeno, opcionalno gdje drugi terapeutski agens je hemoterapeutski agens, kao što su: a) alkilirajuće sredstvo kao što su tiotepa i ciklosfosfamid; b) alkil sulfonat kao što su busulfan, improsulfan i piposulfan; c) aziridini kao što su benzodopa, karbohion, meturedopa, i uredopa; d) etilenimin i metilamelamin uključujući altretamin, trietilenmelamin, trietilenfosforamid, trietilentiofosfaoramid i trimetilolomelamin; e) azotni iperit kao što su hlorambucil, hlornafazin, holofosfamid, estramustin, ifosfamid, mehloretamin, mehloretamin oksid hidrohlorid, melfalan, novembihin, fenesterin, prednimustin, trofosfamid, uracil iperit; f) nitrozurea kao što su karmustin, hlorozotocin, fotemustin, lomustin, nimustin, ranimustin; g) antibiotik kao što je aklacinomisini, aktinomicin, autramicin, azaserin, bleomicini, kaktinomicin, kaliheamicin, karabicin, karminomicin, karzinofilin, hromomicini, daktinomicin, daunorubicin, detorubicin, 6-diazo-5-okso-L-norleucin, doksorubicin, epirubicin, ezorubicin, idarubicin, marcelomicin, mitomicini, mikofenolna kiselina, nogalamicin, olivomicini, peplomicin, potfiromicin, puromicin, hielamicin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimeks, zinostatin, zorubicin; h) anti-metabolit kao što je metotreksat i 5-FU; i) analog folne kiseline kao što su denopterin, metotreksat, pteropterin, trimetreksat; j) purinski analog kao što su fludarabin, 6-merkaptopurin, tiamiprin, tioguanin; k) analog pirimidina kao što su ancitabin, azacitidin, 6-azauridin, karmofur, citarabin, dideoksiuridin, doksifluridin, enocitabin, floksuridin; l) androgen kao što su kalusteron, dromostanolon propionat, epitiostanol, mepitiostan, testolakton; m) anti-andrenalni kao što su aminoglutetimid, mitotan, trilostan; n) dopuna folne kiseline kao što je frolinska kiselina; o) aceglaton; aldofosfamid glikozid; aminolevulinska kiselina; amsakrin; bestrabucil; bisantren; edatraksat; defofamin; demekolcin; diazihion; elfornitin; eliptinium acetat; etoglucid; galijum nitrat; hidroksiurea; lentinan; jonidamin; mitoguazon; mitoksantron; mopidamol; nitracrin; pentostatin; fenamet; pirarubicin; podofilin kiselina; 2-etilhidrazid; prokarbazin; PSK®; razoksan; sizofiran; spirogermanijum; tenuazonska kiselina; triazihion; 2,2’,2"-trihlorotrietilamin; uretan; vindezin; dakarbazin; manomustin; mitobronitol; mitolaktol; pipobroman; gakitozin; arabinozid; ciklofosfamid; ili tiotepa; p) član taksoida ili obitelji taksana, kao što su paklitaksel i njihovi analozi; hlorambucil; gemcitabin; 6-tioguanin; merkaptopurin; metotreksat; q) analog platine kao što su cisplatin i karboplatin; r) vinblastin; platina; etopozid (VP-16); ifosfamid; mitomicin C; mitoksantron; vinkristin; vinorelbin; navelbin; novantron; tenipozid; daunomicin; aminopterin; kseloda; ibandronat; CPT-11; inhibitor topoizomeraze RFS 2000; difluorometilornitin (DMFO); retinoinska kiselina; esperamicini; ili kapecitabin; s) inhibitor receptorskih tirozin kinaza i/ili angiogeneze, uključujući sorafenib, sunitinib pazopanib, toceranib, vandetanib, cediranib, regorafenib, aksitinib (AG013736), lestaurtinib, erlotinib, gefitinib, BIBW 2992, lapatinib, neratinib t) anti-hormonalno sredstvo koje djeluje tako što regulira ili inhibira djelovanje hormona na tumore kao što su anti-estrogeni uključujući na primjer tamoksifen, raloksifen, aromataza inhibirajuće 4(5)-imidazole, 4-hidroksitamoksifen, trioksifen, keoksifen, LI 117018, onapriston, i toremifen; ili u) anti-androgen kao što su flutamid, nilutamid, bikalutamid, leuprolid, i goserelin; i farmaceutski prihvatljive soli, kiseline ili derivate od bilo koga gore navedenog.
HRP20201848TT 2012-11-21 2020-11-20 Bispecifična egfr/c-met antitijela HRP20201848T1 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261728912P 2012-11-21 2012-11-21
US201361782550P 2013-03-14 2013-03-14
US201361809541P 2013-04-08 2013-04-08
US201361864717P 2013-08-12 2013-08-12
US201361892797P 2013-10-18 2013-10-18
EP18199421.1A EP3447069B1 (en) 2012-11-21 2013-11-21 Bispecific egfr/c-met antibodies

Publications (1)

Publication Number Publication Date
HRP20201848T1 true HRP20201848T1 (hr) 2021-01-08

Family

ID=50728148

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20182128TT HRP20182128T1 (hr) 2012-11-21 2013-11-21 Bispecifična egfr/c-met protutijela
HRP20201848TT HRP20201848T1 (hr) 2012-11-21 2020-11-20 Bispecifična egfr/c-met antitijela

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20182128TT HRP20182128T1 (hr) 2012-11-21 2013-11-21 Bispecifična egfr/c-met protutijela

Country Status (36)

Country Link
US (3) US9593164B2 (hr)
EP (4) EP4420727A3 (hr)
JP (6) JP6423357B2 (hr)
KR (3) KR102795571B1 (hr)
CN (2) CN104955838B (hr)
AU (4) AU2013347962B2 (hr)
BR (1) BR112015011717B1 (hr)
CA (2) CA3182876A1 (hr)
CL (1) CL2015001356A1 (hr)
CY (2) CY1121270T1 (hr)
DK (2) DK2922872T3 (hr)
EA (1) EA031184B1 (hr)
ES (3) ES2831374T3 (hr)
FI (1) FIC20220016I1 (hr)
FR (1) FR22C1018I2 (hr)
HR (2) HRP20182128T1 (hr)
HU (3) HUE041499T2 (hr)
IL (1) IL238796B (hr)
LT (3) LT2922872T (hr)
LU (1) LUC00257I2 (hr)
MX (1) MX361088B (hr)
MY (1) MY172867A (hr)
NI (1) NI201500069A (hr)
NL (1) NL301173I2 (hr)
NO (1) NO2022012I1 (hr)
NZ (1) NZ708352A (hr)
PE (1) PE20151181A1 (hr)
PH (1) PH12015501118A1 (hr)
PL (1) PL2922872T3 (hr)
PT (2) PT2922872T (hr)
RS (2) RS58192B1 (hr)
SG (1) SG11201503938VA (hr)
SI (2) SI3447069T1 (hr)
SM (2) SMT201800624T1 (hr)
UA (1) UA117121C2 (hr)
WO (1) WO2014081954A1 (hr)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104497143B (zh) 2007-03-29 2020-08-25 健玛保 双特异性抗体及其制造方法
SI2506871T1 (sl) * 2009-11-30 2016-12-30 Janssen Biotech, Inc. Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami
WO2011110642A2 (en) 2010-03-10 2011-09-15 Genmab A/S Monoclonal antibodies against c-met
JP6040148B2 (ja) * 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
CA3051311A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
DK2771364T3 (da) 2011-10-27 2019-08-19 Genmab As Fremstilling af heterodimere proteiner
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
ES2831374T3 (es) * 2012-11-21 2021-06-08 Janssen Biotech Inc Anticuerpos de EGFR/c-Met biespecíficos
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
KR20160067966A (ko) 2013-10-14 2016-06-14 얀센 바이오테크 인코포레이티드 시스테인 조작된 피브로넥틴 iii형 도메인 결합 분자
HRP20200662T1 (hr) 2014-02-04 2020-10-02 Astellas Pharma Inc. Ljekoviti pripravak koji sadrži spoj diamino heterocikličkog karboksamida kao aktivni sastojak
EP3786186A1 (en) 2014-02-28 2021-03-03 Merus N.V. Antibodies that bind egfr and erbb3
KR102309881B1 (ko) 2014-11-21 2021-10-06 삼성전자주식회사 c-Met 및 EGFR의 이중 저해제 및 IGF-1R 저해제를 포함하는 병용 투여용 약학 조성물
EP3226869A4 (en) * 2014-12-03 2018-07-18 Auckland UniServices, Ltd. Kinase inhibitor prodrug for the treatment of cancer
US11384350B2 (en) 2014-12-15 2022-07-12 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing
CA3008162A1 (en) * 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
EP3233907B1 (en) 2014-12-19 2021-03-03 Genmab A/S Rodent bispecific heterodimeric proteins
DK3237005T3 (en) * 2014-12-22 2024-11-18 Systimmune Inc Bispecific tetravalent antibodies and methods of making and using thereof
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
WO2016182513A1 (en) * 2015-05-13 2016-11-17 Singapore Health Services Pte Ltd Profiling of hepatocellular carcinoma and applications thereof
WO2017069628A2 (en) 2015-10-23 2017-04-27 Merus N.V. Binding molecules that inhibit cancer growth
DK3368571T5 (da) 2015-10-30 2024-09-30 Univ California Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf
KR20250099459A (ko) 2015-11-03 2025-07-01 얀센 바이오테크 인코포레이티드 Pd-1과 특이적으로 결합하는 항체 및 그의 용도
AU2016349152A1 (en) * 2015-11-03 2018-06-14 Merck Patent Gmbh Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
IL260937B2 (en) * 2016-02-06 2024-07-01 Epimab Biotherapeutics Inc Fabs-in-tandem immunoglobulin and uses thereof
AU2017269335B2 (en) 2016-05-26 2021-07-01 Recurium Ip Holdings, Llc EGFR inhibitor compounds
KR101985299B1 (ko) * 2016-06-03 2019-09-03 삼성전자주식회사 항-c-Met/항-Nrp1 이중 특이 항체
AU2017281083B2 (en) 2016-06-21 2022-01-27 Janssen Biotech, Inc. Cysteine engineered fibronectin type III domain binding molecules
JP2019530440A (ja) 2016-09-02 2019-10-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
WO2018094282A1 (en) * 2016-11-18 2018-05-24 The Regents Of The University Of California Engineered antibodies and uses thereof
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
BR112019012154A2 (pt) 2016-12-14 2019-11-12 Janssen Biotech, Inc. domínios do tipo iii da fibronectina de ligação a cd8a
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
EP3576767A4 (en) * 2017-02-06 2020-12-02 Academia Sinica RECOMBINATED PROTEINS AND THEIR USES
US11780925B2 (en) 2017-03-31 2023-10-10 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
US12195551B2 (en) 2017-05-17 2025-01-14 Merus N.V. Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
WO2018221969A1 (en) * 2017-05-30 2018-12-06 Chong Kun Dang Pharmaceutical Corp. A novel anti-c-met antibody and use thereof
AU2018278730B2 (en) * 2017-05-30 2021-02-04 Chong Kun Dang Pharmaceutical Corp. A novel anti-c-Met antibody and use thereof
SI3665198T1 (sl) * 2017-08-09 2025-06-30 Merus N.V. Protitelesa, ki vežejo egfr in cmet
CA3074317C (en) * 2017-08-25 2024-06-18 Janssen Biotech, Inc. Fc.gamma.rii binding fibronectin type iii domains, their conjugates and multispecific molecules comprising them
WO2019114793A1 (zh) * 2017-12-13 2019-06-20 凯惠科技发展(上海)有限公司 一种egfr抗体及其制备方法和应用
US20190184028A1 (en) * 2017-12-14 2019-06-20 Janssen Biotech, Inc. Targeting with firbronectin type iii like domain molecules
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
MA52777A (fr) 2018-05-24 2021-04-14 Janssen Biotech Inc Agents de liaison psma et utilisations correspondantes
US20200061015A1 (en) 2018-08-23 2020-02-27 Janssen Biotech, Inc. Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
KR102871791B1 (ko) 2018-09-10 2025-10-15 미라티 테라퓨틱스, 인크. 병용 요법
WO2020055761A1 (en) * 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
AU2019368816B2 (en) * 2018-10-22 2025-01-30 Janssen Pharmaceutica Nv Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof
CA3112129A1 (en) 2018-12-05 2020-06-11 Mirati Therapeutics, Inc. Combination therapies
TWI874341B (zh) * 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
SG11202108311RA (en) 2019-02-26 2021-09-29 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
AR118720A1 (es) 2019-04-19 2021-10-27 Janssen Biotech Inc Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
KR20220010731A (ko) * 2019-05-14 2022-01-26 얀센 바이오테크 인코포레이티드 이중특이성 항-EGFR/c-Met 항체와 제3 세대 EGFR 티로신 키나제 억제제에 의한 병용 요법
PH12021552798A1 (en) * 2019-05-14 2022-09-19 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
JP7750828B2 (ja) 2019-09-16 2025-10-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫ｐｅｔ撮像のための放射標識されたｍｅｔ結合タンパク質
WO2021076546A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Cd71 binding fibronectin type iii domains
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
US12491255B2 (en) 2019-10-14 2025-12-09 Aro Biotherapeutics Company EPCAM binding fibronectin type III domains
JP7783182B2 (ja) 2020-02-12 2025-12-09 ヤンセン バイオテツク，インコーポレーテツド ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療
EP4135669A1 (en) 2020-04-14 2023-02-22 Janssen Biotech, Inc. Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof
US12528869B2 (en) 2020-08-25 2026-01-20 Janssen Biotech, Inc. Treatment of non-small cell lung cancer with EGFR mutations
AR123340A1 (es) * 2020-08-26 2022-11-23 Janssen Biotech Inc FORMULACIONES ESTABLES QUE COMPRENDEN UN ANTICUERPO BIESPECÍFICO PARA EGFR / c-MET
US20230321087A1 (en) * 2020-09-14 2023-10-12 Janssen Pharmaceutica Nv Fgfr inhibitor combination therapies
KR20230137393A (ko) 2021-01-28 2023-10-04 얀센 바이오테크 인코포레이티드 Psma 결합 단백질 및 이의 용도
JP2024509920A (ja) 2021-03-09 2024-03-05 ヤンセン バイオテツク，インコーポレーテツド Ｅｇｆｒ活性化変異を欠くがんの治療
IL307582A (en) 2021-04-14 2023-12-01 Aro Biotherapeutics Company CD71-binding domains of the fibronectin type
US12239710B2 (en) 2021-04-14 2025-03-04 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
TW202308689A (zh) * 2021-04-21 2023-03-01 美商健生生物科技公司 高濃度的雙特異性抗體調配物
TW202309094A (zh) * 2021-05-18 2023-03-01 美商健生生物科技公司 用於識別癌症患者以進行組合治療之方法
MX2024000501A (es) * 2021-07-14 2024-01-31 Jiangsu Hengrui Pharmaceuticals Co Ltd Molecula de union a antigeno que se une especificamente a hgfr y egfr, y su uso farmaceutico.
WO2023049732A1 (en) 2021-09-21 2023-03-30 Qilu Puget Sound Biotherapeutics Corporation HETERODIMERIC Fc FOR MAKING FUSION PROTEINS AND BISPECIFIC ANTIBODIES
KR20240099227A (ko) * 2021-10-18 2024-06-28 타보텍 바이오테라퓨틱스 (홍콩) 리미티드 항-EGFR 항체, 항-cMET 항체, 항-VEGF 항체, 다중 특이적 항체, 및 이들의 용도
US20230183360A1 (en) * 2021-12-09 2023-06-15 Janssen Biotech, Inc. Use of Amivantamab to Treat Colorectal Cancer
KR20240144944A (ko) 2022-01-28 2024-10-04 온퀄리티 파마슈티컬스 차이나 리미티드 항종양제와 관련된 질병 또는 증상을 예방하거나 치료하는 방법
TW202342057A (zh) 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
US20250188088A1 (en) 2022-02-21 2025-06-12 Onquality Pharmaceuticals China Ltd. Compound and use thereof
CN114740108B (zh) * 2022-03-28 2023-07-14 天津键凯科技有限公司 一种聚合物修饰抗体类药物的修饰度的测定方法
EP4519321A4 (en) * 2022-06-29 2026-01-14 Doma Biopharmaceutical Suzhou Co Ltd EGFR/MET ANTIBODIES AND THEIR USES
MA71324A (fr) 2022-06-30 2025-04-30 Janssen Biotech, Inc. Utilisation d'un anticorps anti-egfr/anti-met pour traiter le cancer gastrique ou oesophagien
WO2025017409A1 (en) 2023-07-14 2025-01-23 Janssen Biotech, Inc. Dosing regimen for therapies comprising bispecific antiegfr/c-met antibodies
WO2024109914A1 (zh) * 2022-11-24 2024-05-30 江苏恒瑞医药股份有限公司 一种包含特异性结合hgfr和egfr的双特异性抗体的药物组合物
JP2026508945A (ja) 2023-03-13 2026-03-13 ヤンセン バイオテツク，インコーポレーテツド 二重特異性抗ＥＧＦＲ／ｃ－Ｍｅｔ抗体と抗ＰＤ－１抗体との併用療法
EP4680648A1 (en) * 2023-03-17 2026-01-21 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-her3 and anti-met antibodies and uses thereof
EP4454706A1 (en) * 2023-04-24 2024-10-30 Universität Stuttgart Novel egfr binding proteins
IL324556A (en) 2023-05-19 2026-01-01 Servier Lab Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
TW202506733A (zh) 2023-06-12 2025-02-16 美商安進公司 淋巴毒素β受體促效劑結合蛋白
KR20260051102A (ko) * 2023-07-07 2026-04-15 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 Egfr/c-met 이중특이적 결합 단백질 및 이의 용도
CN121969654A (zh) * 2023-08-02 2026-05-01 百泰生物药业有限公司 EGFR/c-Met双特异性抗体及其应用
AU2024337472A1 (en) 2023-09-05 2026-04-16 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer
CN122028932A (zh) * 2023-09-28 2026-05-12 上海翰森生物医药科技有限公司 一种双特异性抗体在制备治疗癌症的药物中的用途
WO2025079020A1 (en) 2023-10-12 2025-04-17 Janssen Biotech, Inc. First line treatment in egfr exon 20 insertion-mutated advanced non-small cell lung cancer
CN120000805A (zh) * 2023-11-15 2025-05-16 四川科伦博泰生物医药股份有限公司 靶向EGFR/c-MET的抗体-药物缀合物及其制备方法和用途
TW202532100A (zh) * 2023-12-22 2025-08-16 大陸商信達生物製藥（蘇州）有限公司 靶向b7h3和egfr的雙特異性抗體-藥物偶聯物及其應用
TW202547867A (zh) 2024-01-16 2025-12-16 美商健生生物科技公司 使用阿米維單抗治療結腸直腸癌
EP4716552A1 (en) 2024-01-22 2026-04-01 Janssen Biotech, Inc. Use of amivantamab to treat head and neck cancer
WO2025191459A1 (en) 2024-03-11 2025-09-18 Janssen Biotech, Inc. Use of bispecific anti-egfr/c-met antibodies to treat solid tumors
CN121045388A (zh) * 2024-05-30 2025-12-02 英百瑞(杭州)生物医药有限公司 针对人c-Met和人EGFR的双特异性抗体及其用途
TW202604959A (zh) * 2024-05-31 2026-02-01 大陸商江蘇先聲生物製藥有限公司 抗EGFR×cMet雙特異性抗體的藥物偶聯物及其用途
WO2026017120A1 (zh) * 2024-07-18 2026-01-22 信达生物制药(苏州)有限公司 抗cdh17/egfr/cd16a三特异性抗体及其用途
CA3278557A1 (en) 2024-08-13 2026-03-01 Janssen Biotech, Inc. Methods for reducing dermatologic adverse events in patients treated with egfr/met bispecific antibodies
WO2026038160A1 (en) 2024-08-13 2026-02-19 Janssen Biotech, Inc. Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
WO2026042017A1 (en) 2024-08-19 2026-02-26 Janssen Biotech, Inc. Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc)
WO2026086740A1 (en) 2024-10-21 2026-04-30 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Use and method of bispecific antibody-drug conjugates for treating tumor diseases
WO2026086737A1 (en) 2024-10-21 2026-04-30 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Uses and methods of bispecific antibody-drug conjugates for treating tumor diseases

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2066428C (en) 1989-09-08 2000-11-28 Bert Vogelstein Structural alterations of the egf receptor gene in human gliomas
ES2118066T3 (es) 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
SK281143B6 (sk) 1991-03-06 2000-12-11 Merck Patent Gesellschaft Mit Beschr�Nkter Haftung Chimérická monoklonálna protilátka, expresné vektory a farmaceutický prostriedok
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US20130226834A1 (en) 2000-04-27 2013-08-29 Networth Services, Inc. Systems and methods for determining the financial status of bonds
US7589180B2 (en) 2001-05-11 2009-09-15 Abbott Laboratories Inc. Specific binding proteins and uses thereof
WO2002100348A2 (en) 2001-06-13 2002-12-19 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
JP4602614B2 (ja) 2001-09-26 2010-12-22 アイシン精機株式会社 自動車用ドア
US7842476B2 (en) 2002-09-06 2010-11-30 Isogenica Limited In vitro peptide expression library
EP1592713A2 (en) 2003-02-13 2005-11-09 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
NZ544797A (en) * 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
EP3042964A1 (en) 2004-06-04 2016-07-13 Genentech, Inc. Egfr mutations
PT1773885E (pt) 2004-08-05 2010-07-21 Genentech Inc Antagonistas anti-cmet humanizados
CA2577082A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
ES2529790T3 (es) 2007-04-13 2015-02-25 Dana-Farber Cancer Institute, Inc. Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
US20090042906A1 (en) 2007-04-26 2009-02-12 Massachusetts Institute Of Technology Methods for treating cancers associated with constitutive egfr signaling
EP2190878A1 (en) 2007-09-06 2010-06-02 Genmab A/S Novel methods and antibodies for treating cancer
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
JP2011507521A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ヒト非抗体ペプチド又はタンパク質ファージライブラリ
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
MX2010009669A (es) 2008-03-06 2010-09-22 Genentech Inc Terapia de combinacion con antagonistas de c-met y egfr.
TW201002346A (en) 2008-04-11 2010-01-16 Galaxy Biotech Llc Combination of HGF inhibitor and EGF inhibitor to treat cancer
WO2010019952A2 (en) * 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
US20110229469A1 (en) 2008-10-01 2011-09-22 Ludwig Institute For Cancer Research Methods for the treatment of cancer
BRPI0919881B1 (pt) 2008-10-31 2021-09-08 Centocor Ortho Biotech Inc Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
AU2010233993A1 (en) * 2009-04-07 2011-09-08 Roche Glycart Ag Bispecific anti-ErbB-1/anti-c-Met antibodies
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
AR078254A1 (es) * 2009-09-01 2011-10-26 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
SI2506871T1 (sl) 2009-11-30 2016-12-30 Janssen Biotech, Inc. Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami
WO2011110642A2 (en) * 2010-03-10 2011-09-15 Genmab A/S Monoclonal antibodies against c-met
JP6040148B2 (ja) * 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
JP5997134B2 (ja) 2010-04-30 2016-09-28 ヤンセン バイオテツク，インコーポレーテツド 安定したフィブロネクチンドメイン組成物、方法及び用途
JP2013528394A (ja) * 2010-06-15 2013-07-11 アルベルト・バルデッリ Ｍｌｋ４遺伝子、新規の癌診断および予後マーカー
EP2621953B1 (en) * 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
KR102276792B1 (ko) * 2011-10-10 2021-07-15 시티 오브 호프 메디토프와 메디토프-결합 항체 및 이들의 용도
PL2773671T3 (pl) 2011-11-04 2022-01-24 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc
ES2831374T3 (es) * 2012-11-21 2021-06-08 Janssen Biotech Inc Anticuerpos de EGFR/c-Met biespecíficos
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules

Also Published As

Publication number Publication date
HUE041499T2 (hu) 2019-05-28
AU2021202394A1 (en) 2021-05-20
ES2971536T3 (es) 2024-06-05
JP2026015326A (ja) 2026-01-29
CL2015001356A1 (es) 2015-11-06
JP2021006561A (ja) 2021-01-21
AU2019200441B2 (en) 2021-01-28
EA031184B1 (ru) 2018-11-30
EP3808767B1 (en) 2023-12-06
US20140255408A1 (en) 2014-09-11
CA2893505C (en) 2023-02-21
MX361088B (es) 2018-11-26
NZ708352A (en) 2019-10-25
EP4420727A2 (en) 2024-08-28
UA117121C2 (uk) 2018-06-25
NO2022012I1 (no) 2022-05-06
JP6423357B2 (ja) 2018-11-14
LUC00257I2 (hr) 2025-04-25
AU2021202394B2 (en) 2024-03-07
AU2013347962B2 (en) 2018-10-25
KR102373193B1 (ko) 2022-03-10
DK3447069T3 (da) 2020-11-16
KR20220032654A (ko) 2022-03-15
KR20250054125A (ko) 2025-04-22
FR22C1018I1 (fr) 2022-06-17
RS58192B1 (sr) 2019-03-29
EP3447069B1 (en) 2020-09-23
JP7397105B2 (ja) 2023-12-12
CY1123550T1 (el) 2022-03-24
ES2831374T3 (es) 2021-06-08
EP4420727A3 (en) 2024-10-23
SI3447069T1 (sl) 2021-02-26
EP2922872B1 (en) 2018-10-10
DK2922872T3 (da) 2019-01-02
WO2014081954A1 (en) 2014-05-30
PH12015501118B1 (en) 2016-02-01
PH12015501118A1 (en) 2016-02-01
JP2016505537A (ja) 2016-02-25
US9593164B2 (en) 2017-03-14
PL2922872T3 (pl) 2019-03-29
BR112015011717A2 (pt) 2017-08-15
KR20240005211A (ko) 2024-01-11
US20170101475A1 (en) 2017-04-13
LTC2922872I2 (hr) 2024-09-10
AU2019200441A1 (en) 2019-02-07
PT2922872T (pt) 2019-01-18
EP2922872A1 (en) 2015-09-30
JP2019048817A (ja) 2019-03-28
SG11201503938VA (en) 2015-06-29
AU2024203417A1 (en) 2024-06-13
KR102795571B1 (ko) 2025-04-11
CN104955838A (zh) 2015-09-30
EP3808767C0 (en) 2023-12-06
RS61057B1 (sr) 2020-12-31
PE20151181A1 (es) 2015-08-19
US9695242B2 (en) 2017-07-04
SMT202000619T1 (it) 2021-01-05
CN104955838B (zh) 2021-02-02
JP2022062155A (ja) 2022-04-19
EA201590985A1 (ru) 2015-11-30
LTPA2022507I1 (hr) 2022-06-27
IL238796A0 (en) 2015-06-30
JP6773746B2 (ja) 2020-10-21
EP3447069A1 (en) 2019-02-27
NI201500069A (es) 2015-10-19
CY1121270T1 (el) 2020-05-29
AU2013347962A1 (en) 2015-05-28
HRP20182128T1 (hr) 2019-02-08
FR22C1018I2 (fr) 2023-05-05
HUS2200016I1 (hu) 2022-05-28
JP2024026236A (ja) 2024-02-28
BR112015011717B1 (pt) 2023-12-12
CA3182876A1 (en) 2014-05-30
LT3447069T (lt) 2020-12-10
MY172867A (en) 2019-12-13
ES2700231T3 (es) 2019-02-14
JP7019771B2 (ja) 2022-02-15
PT3447069T (pt) 2020-11-13
FIC20220016I1 (fi) 2022-05-31
HUE052548T2 (hu) 2021-05-28
NL301173I1 (nl) 2022-05-04
MX2015006387A (es) 2015-12-03
IL238796B (en) 2019-06-30
KR20150087365A (ko) 2015-07-29
NL301173I2 (nl) 2022-06-15
US9580508B2 (en) 2017-02-28
US20140141000A1 (en) 2014-05-22
SMT201800624T1 (it) 2019-01-11
EP3808767A1 (en) 2021-04-21
JP7756699B2 (ja) 2025-10-20
CN113201073A (zh) 2021-08-03
EP2922872A4 (en) 2016-07-06
LT2922872T (lt) 2018-12-27
CA2893505A1 (en) 2014-05-30
SI2922872T1 (sl) 2019-01-31

Similar Documents

Publication Publication Date Title
EP3447069A1 (en) Bispecific egfr/c-met antibodies
EP4582100A1 (en) Medicament for treatment and/or prevention of cancer
AU2019242520B2 (en) Pharmaceutical composition for treatment and/or prevention of cancer
CN104271601B (zh) 使用pd-1轴结合拮抗剂和vegf拮抗剂治疗癌症的方法
CA2860941C (en) Combination therapy for the treatment of ovarian cancer
JP2026021441A (ja) 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療
CA3175137A1 (en) Medicament for treatment and/or prevention of cancer
CA2793545A1 (en) Treatment methods
JPWO2021182573A5 (hr)
US20250228937A1 (en) Medicament for treatment and/or prevention of cancer
CA3175277A1 (en) Medicament for treatment and/or prevention of cancer
US20230165957A1 (en) Medicament for treatment and/or prevention of cancer
US20250281607A1 (en) Medicament for treatment and/or prevention of cancer
US20230140155A1 (en) Medicament for treatment and/or prevention of cancer
EP4578457A1 (en) Pharmaceutical for treating and/or preventing cancer
EP4578458A1 (en) Medicament for treatment and/or prevention of cancer
US20240325529A1 (en) Medicament for treatment and/or prevention of cancer
US20260115285A1 (en) Medicament for treatment and/or prevention of cancer
EA050561B1 (ru) Лечение немелкоклеточного рака легкого с мутациями egfr